<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70290">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02190721</url>
  </required_header>
  <id_info>
    <org_study_id>XM02-ONC-201</org_study_id>
    <secondary_id>2014-001772-55</secondary_id>
    <nct_id>NCT02190721</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement</brief_title>
  <official_title>A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of Daily Subcutaneous Administration of 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and
      efficacy of daily subcutaneous administration of 5 μg/kg tbo-filgrastim in infants, children
      and adolescents with solid tumors without bone marrow involvement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with Adverse Events</measure>
    <time_frame>90 Days</time_frame>
    <description>Safety will be assessed by evaluating adverse event reports throughout the study using descriptive statistics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of febrile neutropenia.</measure>
    <time_frame>15 Days</time_frame>
    <description>During cycle 1: The first dose of tbo-filgrastim will be administered after 24 hours (±3 hours) following the end of myelosuppressive chemotherapy (CTX) in week 1 of the study cycle 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in blood lab results</measure>
    <time_frame>Day 1 and 21</time_frame>
    <description>clinical laboratory test results at screening and at the end-of-study visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Vital Signs</measure>
    <time_frame>21 Days</time_frame>
    <description>vital sign measurements at screening, throughout the study treatment, and at the end-of-study visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiography (ECG) findings</measure>
    <time_frame>Day 1, 4 &amp; 6 hours post dose, Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant medication usage</measure>
    <time_frame>90 Days</time_frame>
    <description>Any concomitant medication usage throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spleen sonography</measure>
    <time_frame>Day 1, 4, and 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tolerability at the injection site</measure>
    <time_frame>1 hour (±30 minutes) after each study drug injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody assessment</measure>
    <time_frame>Day 1, 21, and 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>90 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma/serum drug concentration (Cmax)</measure>
    <time_frame>12 Hours</time_frame>
    <description>Up to 12 Hours from Filgrastim administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed drug concentration (tmax)</measure>
    <time_frame>12 Hours</time_frame>
    <description>Up to 12 Hours from Filgrastim administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the serum drug concentration (AUC0-12)</measure>
    <time_frame>12 hours</time_frame>
    <description>area under the serum drug concentration by time curve from time 0 to 12 hours postdose (AUC0-12) Up to 12 Hours from Filgrastim administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration (AUC0-∞)</measure>
    <time_frame>12 Hours</time_frame>
    <description>Up to 12 Hours from Filgrastim administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (t½)</measure>
    <time_frame>12 Hours</time_frame>
    <description>Up to 12 Hours from Filgrastim administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of severe neutropenia (DSN, ANC &lt;0.5 × 109/L)</measure>
    <time_frame>Day 15</time_frame>
    <description>During Cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of absolute neutrophil count (AUCANC)</measure>
    <time_frame>Day 15</time_frame>
    <description>During Cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANC nadir (measured in 109/L)</measure>
    <time_frame>Day 15</time_frame>
    <description>During Cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ANC nadir</measure>
    <time_frame>Day 15</time_frame>
    <description>During Cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ANC recovery to ≥1.0 × 109/L</measure>
    <time_frame>Day 15</time_frame>
    <description>During Cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ANC recovery to ≥2.0 × 109/</measure>
    <time_frame>Day 15</time_frame>
    <description>During Cycle 1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>tbo-filgrastim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive subcutaneous doses of tbo-filgrastim 5 μg/kg body weight daily; each daily dose, to be administered at the investigative site</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tbo-filgrastim</intervention_name>
    <description>5 μg/kg</description>
    <arm_group_label>tbo-filgrastim</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          1. Male or female infants, children and adolescents aged 1 month to &lt;16 years.

          2. Patients with solid tumors without bone marrow involvement, who are scheduled to
             receive myelosuppressive CTX.

          3. Body weight ≥5 kg.

          4. Patients must have an initial diagnosis and histologic proof of their malignancy. All
             enrolled subjects should have signed consent for a CTX regimen that is known to be
             myelotoxic, with counts expected to drop below the absolute neutrophil count (ANC) of
             0.5 × 109/L for at least 3 days. These regimens would include at least one of the
             following:

               -  Etoposide

               -  doxorubicin

               -  ifosfamide

               -  cyclophosphamide

          5. ANC and platelet count: Patients must have an ANC &gt;1 × 109/L and a platelet count
             &gt;100 × 109/L to be eligible for therapy at the start of CTX.

          6. Normal cardiac, renal, and hepatic function.

          7. All subjects must have a life expectancy of 12 weeks or more.

          8. Performance Status: Lansky performance score &gt;60 (age 1 to &lt;16 years).

               -  More criteria may apply, please contact the investigator for more information.

        Exclusion:

          1. Bone marrow involvement.

          2. Active myelogenous leukemia or history of myelogenous leukemia.

          3. Previous treatment with colony-stimulating factors (granulocyte colony-stimulating
             factor [G-CSF], granulocyte-macrophage colony-stimulating factor, interleukin 11
             [IL-11]) less than 6 weeks prior to study entry.

          4. History of congenital neutropenia or cyclic neutropenia.

          5. Pregnant or nursing female patients.

          6. Fertile patients who do not agree to use highly reliable contraceptive measures Prior
             bone marrow or stem cell transplant, or prior radiation to ≥25% of bone marrow within
             the 4 weeks prior to the first tbo-filgrastim dose.

          7. Ongoing active infection or history of infectious disease within 2 weeks prior to the
             screening visit.

          8. Treatment with lithium at screening or planned during the study

               -  More criteria may apply, please contact the investigator for more information.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>TEVA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teva U.S. Medical Information</last_name>
    <phone>1-800-896-5855</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Teva Investigational Site 12951</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 12954</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 12953</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 12959</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 12957</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 60015</name>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 60014</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 60016</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 51185</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 51186</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 51184</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53249</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53248</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53245</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53246</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 52063</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 52064</name>
      <address>
        <city>Cluj-Napoca, Cluj</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50282</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50281</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50284</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50280</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50283</name>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 58147</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 58145</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 58148</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Serbia</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 13, 2017</lastchanged_date>
  <firstreceived_date>July 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neutropenia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
